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 Introduction 
 W hen the University of Michigan (UM) joined the ranks of the Clinical and Translational Science Award (CTSA) 1 consortium in 2007, the Michigan Institute 
for Clinical and Health Research (MICHR) was established to 
support the translation of medical advances throughout our 
institution. Th e importance of clinical research was recognized 
immediately and the clinical research unit (CRU), fi rst established 
in 1977, was embraced as the newly named MICHR Clinical 
Research Unit (MCRU) to form the hub of our clinical translation 
infrastructure. Concomitant with this move, MCRU reevaluated 
its business model and realized that it no longer matched 
closely with the rapidly evolving research portfolio, which was 
increasingly driven by epigenetics, epigenomics, and other 
population-based research. In response, MCRU established a 
new mobile clinical research team, named MCRU 2U, as a way to 
transfer the research skills and expertise of our clinical research 
staff  to the chair or bedside of our research participants. Th e 
guiding metric embraced as an indicator of the MCRU 2U “value-
add” was the enablement of research that would be diffi  cult or 
impossible to carry out in its absence. Th is paper outlines the steps 
taken in pursuit of this metric and the measure of its success, 
highlighting the impacts, benefi ts, and the lessons learned from 
5 years of mobile clinical research at the University of Michigan. 
 Implementing a Mobile Clinical Research Team 
 With the ubiquitous funding squeeze across academic research 
institutions, hybrid academic-business models are evolving 2,3 
to meet the challenge of providing more and improved clinical 
research services with little or no increase in federal resources. 
Moreover, the growing population-based clinical research 
portfolio requires a larger and increasingly diverse participant 
population for successful completion, which means engaging 
more people from vulnerable groups for whom participation 
in clinical research represents additional barriers. 4 Although a 
relatively new concept, mobile clinical research teams are one 
exciting approach to address such issues and they are increasingly 
being employed to engage older populations who are confi ned 
to long-term care facilities, 5 to enroll and screen injection drug 
users, 6 to engage underserved ethnic populations, 7 and to service 
island communities. 8 Despite the rapidly growing interest in the 
concept of mobile clinical research this manuscript is, to our 
knowledge, the fi rst published description of initiating, sustaining 
and growing such a service. Mobilizing our clinical research 
has transformed the overall business model of our CRU from 
an infrastructure-based to a service-based model, positively 
impacting our stakeholders from Principle Investigators (PIs) 
to participants, particularly for historically under-represented 
populations. Our fi ndings may be useful to policymakers and 
university clinical research leadership who wish to adopt or 
expand the mobile clinical research model. 
 Th e main MCRU site is located in a specially designed, state-of-
the-art (2009) facility on the central campus, close to the Medical 
School, the main hospital, and a host of UM medical institutes. 
A satellite clinic provides facilities for the signifi cant participant 
population at the East Medical Campus (approximately 5 miles 
away), including outpatient examination rooms, nursing space, 
and specialized rooms and equipment shared with the Dental 
Research Unit. Our unit has fi ve participant beds for overnight 
stays (approximately 120 per year) and another fi ve that are just 
for ambulatory care (approximately 8,000 per year). Th e genesis 
of MCRU 2U was a single research study back in 2007, which 
required 200+ patients yet recruited only 20. Initially launched as 
an experimental approach to support this and other such “outlier” 
studies, MCRU 2U was activated just 145 times in the fi rst year. 
Th is new “helicopter research” style service quickly became 
indispensable however, and by 2012 the annual participant 
total had risen to almost 2,500, bringing the number of new 
participants served during the 5-year CTSA funding period to 
more than 5,000. Today MCRU 2U represents 20% of our overall 
business and has vastly strengthened our ability to service our 
PI constituency by increasing participation by targeted groups; 
participants from our Mott Children's Hospital are up from 
four per year to 285, while participants in our Comprehensive 
Cancer Center have risen from eight to 861 each year. Despite 
such intense growth, the basic foundations of our model have 
remained remarkably simple. Th e principles underlying MCRU 
2U are primarily to:
•   Extend the practice of clinical research to areas outside 
MCRU, to be inclusive of not only inpatients and outpatients, 
but also their friends and their family members. 
•   Provide vulnerable participants with safe and convenient 
access to the clinical research studies being carried out across 
our extensive hospital complex. 
•   Redesign the participant experience to increase enrollment 
and reduce dropout. 
 Th e ultimate success of a mobile clinical research team depends 
on the eff ectiveness of the implementation strategy.  Figure 1 shows 
our Implementation Plan, which we have supplemented based on 
our experiences and the lessons we have learned. Th e fi rst step 
involves building a strong strategic case, and this means providing 
hard evidence to directly link each identifi ed need to the related 
service gap. Only by clearly demonstrating this link can the service 
gap form the basis of the impact analysis. In our case the research 
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needs were driven by an increasingly population-based research 
portfolio, high in epigenetics and epigenomics studies. Participant 
recruitment and retention was another tactical challenge 9,10 and 
when we examined our service gaps we discovered that limiting 
our participant base to our clinical research infrastructure was 
restricting access to services for strategically important participant 
groups. In particular, this was impacting our growing portfolio 
of hospitalized cancer patients and newly diagnosed Phase I 
 Figure 1.  Implementation Plan for a mobile clinical research team, detailing strategy, implementation, opera-
tion and growth steps with Key Deliverables highlighted for each stage. 
participants, who require support at the 
bedside because they are unable to travel to 
the CRU. Th ese issues added up to signifi cant 
lost opportunities for us in our strategic case. 
 The mainstay of our business case 
involved generating a cost-benefi t analysis to 
demonstrate that the proposal was justifi ed. 
In our experience, more than 70% of the 
procedures for which MCRU 2U is called 
upon are simple phlebotomy ( Figure 2 ). Th is is 
a very good indicator for assessing the return 
on investment (ROI) when introducing 
a mobile team; it can be largely a Medical 
Assistant (MA) driven service and the costs 
for phlebotomy supplies are modest ( Table 1 ). 
Further, initiating and operating this service 
is highly cost eff ective because it involves no 
additional outlay for infrastructure costs. Th is 
cost calculation balances favorably against 
the potential opportunities in leveraging a 
huge new participant population, in addition 
to increasing the number and speed of study 
completions. In our case, our ROI has been 
profound and we have signifi cantly increased 
our business overall (see  Figure 2 ) without 
increasing costs. Th e design of our business 
model was driven by our strategic case and we 
determined that the value-add to our clinical 
research enterprise, albeit in non-dollar form, 
was potentially so signifi cant that MCRU 
2U should be fully funded through CTSA 
and institutional contributions. Th erefore, 
in order to fi rmly establish this new service, 
the PIs were not charged for activating 
the MCRU 2U team, with the intention of 
transitioning to a sustainable business model 
at a later date. At this point we undertook 
no direct advertising campaign which was, 
with hindsight, the right decision. Requests 
increased through word of mouth about as 
fast as we could grow to meet them, so more 
demand could have swamped our nascent 
service model. 
 Implementation of this new service 
relied on the engagement of our most 
experienced staff . Clinical research nurses 
are highly specialized, operating at the front 
line of research eff orts, 11 and this in-depth 
knowledge put them in a critical position 
to form our Implementation Team and 
drive our Implementation Plan, by clearly 
communicating the responsibilities and 
metrics of each individual and then holding 
them accountable for the outcomes. Th eir 
expertise was balanced by multidisciplinary input from other 
stakeholders via our Advisory Team, which included not only 
associated PIs and leadership, but also ethics and regulatory 
representatives. Th is collaborative helped us identify known 
barriers and develop eff ective strategies to address them, as well 
as develop clear goals, expectations, milestones, and timelines. 
High level champions form a crucial part of this process because 
they work with institutional leadership and the wider research 
 Figure 2.  Growth of the mobile clinical research team during the fi rst CTSA funding period; (a) MCRU 2U has 
serviced more than 5,000 research participants over the lifetime of the CTSA grant, with 2,414 participants 
in the grant year 2011–2012 alone (1,575 scheduled and 839 just-in-time visits). (b) The number of activa-
tions for each service area can vary widely depending on the protocol portfolio but overall the calls to each 
area are on the rise. The most popular locations for grant year 2011–2012 were the Comprehensive Cancer 
Center (861) and the Taubman Health Care Center (579). (c) The most requested service is phlebotomy, 
which for grant year 2011–2012 totaled 2,229. 
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community to address resistance and act as “ambassadors” to 
promote the team's successes. As we progressed, the Advisory 
Team helped us to identify new barriers and quickly make 
improvements or changes as needed. Th e development of a 
regulatory compliance and document management system is 
of distinct importance during this stage of the implementation, 
since a mobile team can be particularly vulnerable in areas such 
as participant privacy and sample integrity. A key issue here is that 
we monitored our progress from the start, by defi ning a Metrics 
Map to ensure that the data we tracked were actually related to our 
success (or not!) via a direct link to our Key Deliverables. 12 Some 
of these measured core outcomes have evolved over the CTSA 
funding period and the major metrics we now use to evaluate 
growth and success are shown in  Figure 2 a–c. 
 Although we did not actively advertise MCRU 2U, we did 
develop a Communication Plan by which MCRU PIs were made 
aware of the mobile services on off er and how they may access 
them. We off er four routes for MCRU 2U activation: (1) walk-in, 
where a PI may direct a participant to the CRU for immediate 
service; (2) Just-in-time, where a research team member is 
dispatched immediately to a hospital location external to the CRU; 
(3) prescheduled services at locations external to the CRU; and 
(4) the impromptu set-up of a temporary research “clinic” at any 
location. In terms of operation, the initial PI/study team request 
is assessed by MCRU staff  and, depending on the complexity of 
the service requested, a Research Nurse or an MA is assigned. 
Importantly, when we introduced MCRU 2U we did not hire 
additional personnel, but instead reassigned and repurposed 
the original staff  to incorporate this new service platform. We 
discovered that it is not feasible to identify a single individual 
to cover MCRU 2U requests because there are oft en multiple 
calls simultaneously for different locations. Even if several 
participants are in the same place, off ering a single MCRU 2U 
team member could mean an unacceptable wait for the last one to 
be seen. Since CRUs typically operate under 
a feast-or-famine model, an area of initial 
concern here was that having a number of 
staff  on MCRU 2U calls without any lead 
time could compromise the operation of 
the unit. In practice however, we have found 
that the speed and fl exibility of the mobile 
team means we can work around them. In 
addition, we retain the right that, if required, 
the team member negotiates with the study 
team to redirect their participant to the 
unit, although in 5 years this has never been 
necessary. Over time we have developed 
working guidelines and best practices for 
the smooth operation of our service and, 
of the protocols we have developed, the 
most important are regulatory compliance, 
maintaining the chain of sample custody, and 
protecting the integrity of the sample (both 
physically and through documentation). 
Informed consent is protected in two ways 
with MCRU 2U; the fi rst is for scheduled visits, 
where informed consent documentation 
is confi rmed within the electronic medical 
records, and the second is for just-in-time 
appointments, where the documentation is 
provided to the MCRU 2U team member 
at the point of participant interaction, and is confi rmed before 
any service is carried out. In the case of our community nurse, 
informed consent can be carried out in two ways; the fi rst is before 
a scheduled visit, where the nurse can check the documentation 
in the electronic medical records or request a faxed copy. Th e 
second applies where the community nurse is participating in a 
population study, e.g., in a community center, where she partners 
with the study coordinator on-site and consent is obtained in real 
time. A particular strength of our model is that adaptations and 
improvements are made in real time through feedback during 
monthly meetings and it is fair to say that this is the foundation 
for much of our success in implementing and sustaining the team. 
 In the past 5 years we have consistently looked for innovative 
ways to service our clinical research studies better and we share 
here some of those which are, in our experience, the most valuable. 
Adding a community-based mobile research nurse, who travels 
up to 1 hour drive from our clinic, a distance of approximately 
100 miles diameter, has built an additional layer of diversity 
into our participant base by avoiding exclusion on such criteria 
as social or economic grounds. However, because the resulting 
samples are obtained outside the regulated environment of the 
hospital they require new considerations, for example, regarding 
infection control and transport time. We have also found that 
pre-empting demand at strategic locations or time periods by 
setting up impromptu clinics is another highly effi  cient approach 
for population-based studies. As an MA-driven service, and 
because our CRU off ers overnight services by a Research Nurse 
and an MA, we have extended our business model to off er a 
24-hour MCRU 2U service at minimal cost. In addition, we are 
also looking at ways to network with primary care doctors who 
partner with researchers, as this is where patients will be seen 
repetitively. 
 Looking back over the past 5 years, we can clearly identify the 
three most crucial success factors for our mobile team. Almost 
Equipment needs for a hospital-based 
MCRU-2U member
Equipment needs for a community-based 
MCRU-2U member
Phlebotomy tubes, 2×2 sterile gauze, 
23 and 21 gauge needles, central line 
supplies, syringes (3cc), alcohol and blue 
pads, tourniquet, coban, urine cups.
Phlebotomy tubes, 2×2 sterile gauze, 23 
and 21 gauge needles, central line sup-
plies, syringes (3cc), alcohol and blue pads, 
tourniquet, coban, urine cups.
Biohazard sharps container (small), 
gloves, band aids, towelettes (e.g., to 
clean area for urine collections), sample 
labels.
Biohazard sharps container (pint), gloves, 
band aids, towelettes (e.g., to clean area 
for urine collections), sample labels, blood 
pressure machine, and weight scale (kg).
Pager and/or mobile phone. Pager and/or mobile phone.
Documentation, * e.g., IRB paperwork, 
protocol specifi c clinical sheet.
Documentation, * e.g., IRB paperwork, proto-
col specifi c clinical sheet.
Biohazard bags and ice pack for sample 
transport.
Biohazard bags for sample transport in 
specialized cooler.
Maps (for our vast hospital space), pens. Mapquest, GPS system, portable clipboard 
storage case, pens.
Backpack (some members opt for 
a  rolling suitcase when additional 
 equipment is required).
Rolling backpack and wheeled crate.
* Informed consent is not included here because this is verifi ed online before the visit or a copy is provided during 
the site visit. 
 Table 1.  The different equipment needs for mobile clinical research in the hospital and in the community. 
Because there are often additional or unexpected requests upon arrival, we routinely carry surplus supplied, e.g., 
extra tubes. Because the community-based nurse is provided with a car it is possible to include some heavier 
pieces of equipment. 
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60% of participants recruited through MCRU 2U are new to 
research, many of whom had not planned to become a participant 
but agreed to participate in a study during a regular health service 
appointment. Th eir willingness to contribute largely rests on their 
participation not taking up a substantial amount of time and, as 
such, the leading key success factor for participants is speed. Th e 
average response for just-in-time MCRU 2U activations is just 19 
minutes and this success is backed by survey measured impact, 
with 100% of MCRU 2U participants confi rming that they would 
recommend participation to a friend. 13 From the PI perspective, 
responsiveness is the critical success factor, particularly for studies 
with a rare or limited target population where they must be able to 
take advantage of every opportunity to recruit a new participant. 
Th is means being willing to travel to wherever the participant is 
located and off ering maximum fl exibility on the services off ered. 
MCRU 2U has six major centers within the UM health system 
where we regularly carry out services and for any other location, 
if we can physically get there, we will service a participant there. 
Similarly, if the need for a new service arises and it is physically 
possible to carry it out using equipment that can fi t in a back-
pack, we will off er it. 
 Conclusions and Future Prospects 
 MCRU 2U has positively impacted all our clinical research 
stakeholders and revolutionized the way our CRU does business. 
Researchers can now reach participants who would otherwise 
be inaccessible such as those in ICUs, and can more easily 
undertake complicated research studies such as those requiring 
the collection of time sensitive pharmacokinetics/biomarkers. 
The most important stakeholders however are the research 
participants and MCRU 2U participants are truly patients fi rst, 
representing populations that have historically been excluded 
from participating in research due to mobility, impairment, 
socioeconomic and other factors. MCRU 2U has signifi cantly 
reduced the barriers to participation for these groups. 
 Th e impact of the MCRU 2U service for this CTSA funding 
period is clear and, having had our award renewed in recent 
months, we are now looking forward to the next 5 years and 
even more progress. Th e breakneck pace at which technology 
is advancing means the population-based research portfolio 
will likely continue to grow rapidly, and mobile clinical research 
teams off er one of the most promising ways to meet the ever-
increasing demand for sample numbers. Clinical research is a 
critical and dynamic component of the translational pathway and 
CRUs throughout the CTSA are working hard to preempt future 
challenges, as we ask ourselves: How we can position our clinical 
research services for the next generation of clinical research? 
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